The guanine-based purinergic system: The tale of an orphan neuromodulation

Natale Belluardo, Giuseppa Mudo', Valentina Di Liberto, Monica Frinchi, Francesco Caciagli, Francisco Ciruela, Patrizia Di Iorio, Renata Ciccarelli, Víctor Fernandez-Dueñas, Daniele F. Condorelli, Roberta Garozzo

Risultato della ricerca: Review article

10 Citazioni (Scopus)

Abstract

Guanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial functional interplay between GBPs effects and adenosine receptors activity has been recently described, thus triggering the hypothesis that GBPs mechanism of action might somehow involve adenosine receptors. Here, we review recent data describing the GBPs role in the brain. We focus on the involvement of GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs receptors. Overall, we expect to shed some light on the GBPs world since although these molecules might represent excellent candidates for certain neurological diseases management, the lack of putative GBPs receptors precludes any high throughput screening intent for the search of effective GBPs-based drugs.
Lingua originaleEnglish
pagine (da-a)158-
Numero di pagine15
RivistaFrontiers in Pharmacology
Volume7
Stato di pubblicazionePublished - 2016

Fingerprint

Guanine
Purines
Purinergic Receptors
Neuronal Plasticity
Purinergic P1 Receptors
Disease Management
Neurotransmitter Agents
Central Nervous System

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cita questo

The guanine-based purinergic system: The tale of an orphan neuromodulation. / Belluardo, Natale; Mudo', Giuseppa; Di Liberto, Valentina; Frinchi, Monica; Caciagli, Francesco; Ciruela, Francisco; Di Iorio, Patrizia; Ciccarelli, Renata; Fernandez-Dueñas, Víctor; Condorelli, Daniele F.; Garozzo, Roberta.

In: Frontiers in Pharmacology, Vol. 7, 2016, pag. 158-.

Risultato della ricerca: Review article

Belluardo, N, Mudo', G, Di Liberto, V, Frinchi, M, Caciagli, F, Ciruela, F, Di Iorio, P, Ciccarelli, R, Fernandez-Dueñas, V, Condorelli, DF & Garozzo, R 2016, 'The guanine-based purinergic system: The tale of an orphan neuromodulation', Frontiers in Pharmacology, vol. 7, pagg. 158-.
Belluardo, Natale ; Mudo', Giuseppa ; Di Liberto, Valentina ; Frinchi, Monica ; Caciagli, Francesco ; Ciruela, Francisco ; Di Iorio, Patrizia ; Ciccarelli, Renata ; Fernandez-Dueñas, Víctor ; Condorelli, Daniele F. ; Garozzo, Roberta. / The guanine-based purinergic system: The tale of an orphan neuromodulation. In: Frontiers in Pharmacology. 2016 ; Vol. 7. pagg. 158-.
@article{aa706aac736a4e998880602482ee7c08,
title = "The guanine-based purinergic system: The tale of an orphan neuromodulation",
abstract = "Guanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial functional interplay between GBPs effects and adenosine receptors activity has been recently described, thus triggering the hypothesis that GBPs mechanism of action might somehow involve adenosine receptors. Here, we review recent data describing the GBPs role in the brain. We focus on the involvement of GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs receptors. Overall, we expect to shed some light on the GBPs world since although these molecules might represent excellent candidates for certain neurological diseases management, the lack of putative GBPs receptors precludes any high throughput screening intent for the search of effective GBPs-based drugs.",
author = "Natale Belluardo and Giuseppa Mudo' and {Di Liberto}, Valentina and Monica Frinchi and Francesco Caciagli and Francisco Ciruela and {Di Iorio}, Patrizia and Renata Ciccarelli and V{\'i}ctor Fernandez-Due{\~n}as and Condorelli, {Daniele F.} and Roberta Garozzo",
year = "2016",
language = "English",
volume = "7",
pages = "158--",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The guanine-based purinergic system: The tale of an orphan neuromodulation

AU - Belluardo, Natale

AU - Mudo', Giuseppa

AU - Di Liberto, Valentina

AU - Frinchi, Monica

AU - Caciagli, Francesco

AU - Ciruela, Francisco

AU - Di Iorio, Patrizia

AU - Ciccarelli, Renata

AU - Fernandez-Dueñas, Víctor

AU - Condorelli, Daniele F.

AU - Garozzo, Roberta

PY - 2016

Y1 - 2016

N2 - Guanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial functional interplay between GBPs effects and adenosine receptors activity has been recently described, thus triggering the hypothesis that GBPs mechanism of action might somehow involve adenosine receptors. Here, we review recent data describing the GBPs role in the brain. We focus on the involvement of GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs receptors. Overall, we expect to shed some light on the GBPs world since although these molecules might represent excellent candidates for certain neurological diseases management, the lack of putative GBPs receptors precludes any high throughput screening intent for the search of effective GBPs-based drugs.

AB - Guanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial functional interplay between GBPs effects and adenosine receptors activity has been recently described, thus triggering the hypothesis that GBPs mechanism of action might somehow involve adenosine receptors. Here, we review recent data describing the GBPs role in the brain. We focus on the involvement of GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs receptors. Overall, we expect to shed some light on the GBPs world since although these molecules might represent excellent candidates for certain neurological diseases management, the lack of putative GBPs receptors precludes any high throughput screening intent for the search of effective GBPs-based drugs.

UR - http://hdl.handle.net/10447/283412

UR - http://journal.frontiersin.org/article/10.3389/fphar.2016.00158/full

M3 - Review article

VL - 7

SP - 158-

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

ER -